Related Experiment Videos
Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy
JAMA
|November 8, 1976
Summary
Adjuvant immunotherapy using bacillus Calmette-Guérin (BCG) and tumor cell vaccine shows promise for localized soft tissue sarcoma. Patients receiving immunotherapy had better disease-free survival rates and longer intervals before recurrence compared to surgery alone.
Area of Science:
- Oncology
- Immunology
- Surgical Oncology
Background:
- Evidence suggests an active immune response against sarcoma.
- Soft tissue sarcoma treatment often involves surgery, but recurrence is a concern.
Purpose of the Study:
- To evaluate the efficacy of adjuvant immunotherapy in patients with localized soft tissue sarcoma.
- To compare outcomes between immunotherapy and operation alone.
Main Methods:
- A clinical trial was conducted involving adjuvant immunotherapy with bacillus Calmette-Guérin (BCG) and tumor cell vaccine.
- Patients with localized soft tissue sarcoma were assigned to immunotherapy or operation alone.
Main Results:
- Eleven of 18 patients (61%) receiving immunotherapy were disease-free, compared to 5 of 15 (33%) treated by operation alone.
- The median disease-free interval for patients with recurrence was extended from 7.3 to 15 months with immunotherapy.
Conclusions:
- Adjuvant immunotherapy demonstrates potential in improving disease-free survival for soft tissue sarcoma.
- Immunotherapy may prolong disease-free intervals in patients experiencing recurrence.